Bausch + Lomb Corp (BLCO)vsNovartis AG ADR (NVS)
BLCO
Bausch + Lomb Corp
$16.18
+1.70%
HEALTHCARE · Cap: $5.67B
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1009% more annual revenue ($56.58B vs $5.10B). NVS leads profitability with a 23.9% profit margin vs -7.1%. BLCO appears more attractively valued with a PEG of 0.89. NVS earns a higher WallStSmart Score of 51/100 (C-).
BLCO
Hold47
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.6%
Fair Value
$40.13
Current Price
$16.18
$23.95 discount
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Weak financial health signals
ROE of -5.4% — below average capital efficiency
Earnings declined 88.6%
Negative free cash flow — burning cash
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BLCO
The strongest argument for BLCO centers on Price/Book, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : BLCO
The primary concerns for BLCO are Piotroski F-Score, Return on Equity, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BLCO profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
BLCO carries more volatility with a beta of 0.59 — expect wider price swings.
BLCO is growing revenue faster at 9.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 47/100), backed by strong 23.9% margins. BLCO offers better value entry with a 57.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bausch + Lomb Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?